Table 1.
Baseline characteristics of participants included in genetic association analyses
| Total (n=72) | Control Group (n=25) | Efavirenz Group (n=24) | Atazanavir/r Group (n=23) | |
|---|---|---|---|---|
| Age in years, median (range) | 34.0 (22 – 55) | 31 (22 – 48) | 36 (24 – 55) | 37 (24 – 48) |
| Sex (female); n (%) | 72 (100) | 25 (100) | 24 (100) | 23 (100) |
| Race/Ethnicity; n (%) | ||||
| White | 3 (4) | 1 (4) | 1 (4) | 1 (4) |
| Black | 35 (49) | 11 (44) | 16 (64) | 9 (39) |
| Asian/ Pacific Islandera | 8 (11) | 3 (12) | 0 (0) | 5 (22) |
| Hispanic | 26 (36) | 10 (40) | 8 (32) | 8 (35) |
| Weight in kg, median (range) | 67.5 (36.9 – 170.6) | 66.8 (36.9 – 112.9) | 68.9 (46.5 – 170.6) | 64 (47.3 – 152.4) |
| CYP2B6 metabolizer genotype; n (%) | ||||
| normal | 22 (31) | 5 (20) | 9 (38) | 8 (35) |
| intermediate | 32 (44) | 12 (48) | 7 (29) | 13 (57) |
| slow | 18 (25) | 8 (32) | 8 (33) | 2 (9) |
a
defined based on NIH policy on reporting race and ethnicity data.